Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q18355303> ?p ?o }
Showing triples 1 to 46 of
46
with 100 triples per page.
- Q18355303 subject Q7334131.
- Q18355303 subject Q7335338.
- Q18355303 subject Q7335370.
- Q18355303 subject Q8703495.
- Q18355303 subject Q8727262.
- Q18355303 abstract "Filorexant (INN, USAN) (code name MK-6096) is an orexin antagonist which is or was under development by Merck for the treatment of insomnia. It is a dual antagonist of the OX1 and OX2 receptors. As of March 2014, filorexant has completed phase II clinical trials. It was also investigated as a migraine prophylaxis, but was not found effective, and in major depressive disorder and painful diabetic neuropathy. As of May 2015, filorexant is no longer listed on Merck's online development pipeline.".
- Q18355303 atcPrefix "none".
- Q18355303 casNumber "1088991-73-4".
- Q18355303 iupacName "[(2R,5R)-5-{[(5-Fluoro-2-pyridinyl)oxy]methyl}-2-methyl-1-piperidinyl][5-methyl-2-(2-pyrimidinyl)phenyl]methanone".
- Q18355303 pubchem "25128145".
- Q18355303 thumbnail Filorexant.svg?width=300.
- Q18355303 wikiPageWikiLink Q133823.
- Q18355303 wikiPageWikiLink Q1773974.
- Q18355303 wikiPageWikiLink Q18026851.
- Q18355303 wikiPageWikiLink Q18026854.
- Q18355303 wikiPageWikiLink Q1869874.
- Q18355303 wikiPageWikiLink Q2046550.
- Q18355303 wikiPageWikiLink Q20707990.
- Q18355303 wikiPageWikiLink Q247489.
- Q18355303 wikiPageWikiLink Q30612.
- Q18355303 wikiPageWikiLink Q410943.
- Q18355303 wikiPageWikiLink Q42844.
- Q18355303 wikiPageWikiLink Q4355941.
- Q18355303 wikiPageWikiLink Q4926095.
- Q18355303 wikiPageWikiLink Q7101688.
- Q18355303 wikiPageWikiLink Q7180990.
- Q18355303 wikiPageWikiLink Q7334131.
- Q18355303 wikiPageWikiLink Q7335338.
- Q18355303 wikiPageWikiLink Q7335370.
- Q18355303 wikiPageWikiLink Q7388914.
- Q18355303 wikiPageWikiLink Q7650517.
- Q18355303 wikiPageWikiLink Q824258.
- Q18355303 wikiPageWikiLink Q8703495.
- Q18355303 wikiPageWikiLink Q8727262.
- Q18355303 atcPrefix "none".
- Q18355303 casNumber "1088991".
- Q18355303 iupacName "[-5-{[oxy]methyl}-2-methyl-1-piperidinyl][5-methyl-2-phenyl]methanone".
- Q18355303 pubchem "25128145".
- Q18355303 type ChemicalSubstance.
- Q18355303 type Drug.
- Q18355303 type ChemicalObject.
- Q18355303 type Thing.
- Q18355303 type Q8386.
- Q18355303 comment "Filorexant (INN, USAN) (code name MK-6096) is an orexin antagonist which is or was under development by Merck for the treatment of insomnia. It is a dual antagonist of the OX1 and OX2 receptors. As of March 2014, filorexant has completed phase II clinical trials. It was also investigated as a migraine prophylaxis, but was not found effective, and in major depressive disorder and painful diabetic neuropathy. As of May 2015, filorexant is no longer listed on Merck's online development pipeline.".
- Q18355303 label "Filorexant".
- Q18355303 depiction Filorexant.svg.